Boston Scientific Files 8-K on Financials

TL;DR

BSX filed an 8-K on July 23rd detailing financial results and operations.

AI Summary

Boston Scientific Corporation filed an 8-K on July 23, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 300 Boston Scientific Way, Marlborough, Massachusetts.

Why It Matters

This filing provides investors with crucial updates on Boston Scientific's financial performance and operational status, impacting investment decisions.

Risk Assessment

Risk Level: low — This is a routine financial reporting filing with no immediate indication of significant new risks.

Key Players & Entities

• Boston Scientific Corporation (company) — Registrant
• July 23, 2025 (date) — Date of report
• Marlborough, Massachusetts (location) — Principal executive offices
• 300 Boston Scientific Way (address) — Business and mailing address

FAQ

From the Filing

0000885725-25-000039.txt : 20250723 0000885725-25-000039.hdr.sgml : 20250723 20250723063254 ACCESSION NUMBER: 0000885725-25-000039 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20250723 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250723 DATE AS OF CHANGE: 20250723 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BOSTON SCIENTIFIC CORP CENTRAL INDEX KEY: 0000885725 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 042695240 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11083 FILM NUMBER: 251141575 BUSINESS ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 BUSINESS PHONE: 508-683-4000 MAIL ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 8-K 1 bsx-20250723.htm 8-K bsx-20250723 0000885725 false 0000885725 2025-07-23 2025-07-23 0000885725 us-gaap:CommonStockMember 2025-07-23 2025-07-23 0000885725 bsx:SeniorNotedue2027Member 2025-07-23 2025-07-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 _____________________________________________________________________ FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 _____________________________________________________________________ Date of Report (Date of earliest event reported): July 23, 2025 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.)      300 Boston Scientific Way , Marlborough , Massachusetts                  01752-1234     (Address of Principal Executive Offices)                           (Zip Code) 508 683-4000 (Registrant's telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common Stock, $0.01 par value per share BSX New York Stock Exchange 0.625% Senior Notes due 2027 BSX27 New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company    ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐ ITEM 2.02.    RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On July 23, 2025, Boston Scientific Corporation issued a press release announcing financial results for the second quarter ended June 30, 2025. A copy of the release